Literature DB >> 637586

Heparin in the treatment of experimental peritonitis.

T Hau, R L Simmons.   

Abstract

Two experiments were performed to determine the effect of heparin on experimental fibrinopurulent peritonitis in dogs. Peritonitis was induced by the creation of a 10 cm long isolated loop of terminal ileum. In a first experiment comprising 24 dogs the necrotic loop was removed 24 hours later without cleaning or irrigating the peritoneal cavity. All dogs showed fibrino-purulent peritonitis at that time. No antibiotics were given. All dogs received 500 ml of Ringer's lactate during surgery and were allowed p.o. fluids on the first postoperative day. At the time of excision the dogs were blindly randomized into a control group and two treatment groups receiving heparin 100 u/kg i.p. or s.c. respectively. Of the eight animals in the control group, five died of peritonitis and two showed residual intraperitoneal sepsis at the time of sacrifice 14 days after the initial surgery. Thus, only one dog cleared his peritoneal infection spontaneously. Of the heparin treated dogs six out of eight in the i.p. treated and seven out of eight in the s.c. treated group cleared their peritonitis spontaneously within 14 days (p </= 0.05 and 0.02 respectively). In a second experiment peritonitis was induced in 24 dogs as described above, but the necrotic loop was not removed. The dogs were blindly randomized to daily low dose heparin (50 u/kg s.c. b.i.d.) or no therapy. Only two out of 12 dogs of the control group survived the observation period of 14 days compared with eight out of 12 of the heparin treated group (p </= 0.05). However, in all dogs in this experiment residual i.p. sepsis was found. We conclude that heparin has a therapeutic effect in experimental canine peritonitis by preventing the additional apposition of fibrin and, thus, rendering the bacteria more susceptible to cellular and noncellular clearing mechanisms.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 637586      PMCID: PMC1396420          DOI: 10.1097/00000658-197803000-00014

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  22 in total

1.  A STUDY OF SOME FACTORS AFFECTING THE MORTALITY RATE IN DIFFUSE PERITONITIS.

Authors:  J L DAWSON
Journal:  Gut       Date:  1963-12       Impact factor: 23.059

2.  [ON RELATIONS BETWEEN FIBRINOLYSIS AND INTERPERITONEAL ADHESIONS].

Authors:  H BENZER; G BLUEMEL; F PIZA
Journal:  Wien Klin Wochenschr       Date:  1963-12-06       Impact factor: 1.704

3.  INFLAMMATION IN SEROUS CAVITIES; DEFINITION AND MEASUREMENT.

Authors:  E L OPIE
Journal:  Arch Pathol       Date:  1964-07

4.  AN EVALUATION OF THE EFFECT OF FIBRINOLYSIN ON INTRAPERITONEAL ADHESION FORMATION.

Authors:  L R BRYANT
Journal:  Am J Surg       Date:  1963-12       Impact factor: 2.565

5.  Observations of intraperitoneal adhesions; an experimental study.

Authors:  B B JACKSON
Journal:  Surgery       Date:  1958-09       Impact factor: 3.982

6.  Functional significance of histamine and heparin in tissue mast cells.

Authors:  J F RILEY
Journal:  Ann N Y Acad Sci       Date:  1963-02-26       Impact factor: 5.691

7.  The effect of fibrinolysin and heparin on the formation of peritoneal adhesions.

Authors:  J J KNIGHTLY; D AGOSTINO; E E CLIFFTON
Journal:  Surgery       Date:  1962-07       Impact factor: 3.982

8.  The identity and origin of the anticoagulant of anaphylactic shock in the dog.

Authors:  L B Jaques; E T Waters
Journal:  J Physiol       Date:  1941-06-30       Impact factor: 5.182

9.  THE PREVENTION OF PERITONEAL ADHESIONS WITH HEPARIN: AN EXPERIMENTAL STUDY.

Authors:  E P Lehman; F Boys
Journal:  Ann Surg       Date:  1940-03       Impact factor: 12.969

10.  Studies on inflammation. 1. The effect of histamine and serotonin on vascular permeability: an electron microscopic study.

Authors:  G MAJNO; G E PALADE
Journal:  J Biophys Biochem Cytol       Date:  1961-12
View more
  9 in total

1.  Omentum prevents intestinal adhesions to mesh graft in abdominal infections and serosal defects.

Authors:  B Karabulut; K Sönmez; Z Türkyilmaz; B Demiroğullari; R Karabulut; C Sezer; N Sultan; A C Başaklar; N Kale
Journal:  Surg Endosc       Date:  2006-05-11       Impact factor: 4.584

2.  Mesenteric thrombus associated with pulmonary, splenic, portal, and caval thrombi in a dog that was presented for an acute abdomen.

Authors:  Adam Joseph Rudinsky; Valerie Jill Parker; Julien Guillaumin
Journal:  Can Vet J       Date:  2016-10       Impact factor: 1.008

3.  Adjuvant effect of heparin on peritonitis induced in rats.

Authors:  M M Bagree; R K Aneja
Journal:  Jpn J Surg       Date:  1983-11

Review 4.  The effect of heparin administration in animal models of sepsis: a prospective study in Escherichia coli-challenged mice and a systematic review and metaregression analysis of published studies.

Authors:  Yan Li; Jun-Feng Sun; Xizhong Cui; Haresh Mani; Robert L Danner; Xuemei Li; Jun-Wu Su; Yvonne Fitz; Peter Q Eichacker
Journal:  Crit Care Med       Date:  2011-05       Impact factor: 7.598

5.  Disparate mechanisms of induction of procoagulant activity by live and inactivated bacteria and viruses.

Authors:  S B Sinclair; O D Rotstein; G A Levy
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

6.  Fibrin in peritonitis. V. Fibrin inhibits phagocytic killing of Escherichia coli by human polymorphonuclear leukocytes.

Authors:  O D Rotstein; T L Pruett; R L Simmons
Journal:  Ann Surg       Date:  1986-04       Impact factor: 12.969

7.  Induction of macrophage procoagulant activity by Bacteroides fragilis.

Authors:  G A Rosenthal; G Levy; O D Rotstein
Journal:  Infect Immun       Date:  1989-02       Impact factor: 3.441

8.  The role of feces, necrotic tissue, and various blocking agents in the prevention of adhesions.

Authors:  J P O'Leary; G Wickbom; S O Cha; A Wickbom
Journal:  Ann Surg       Date:  1988-06       Impact factor: 12.969

9.  Microvascular endothelial dysfunction: a renewed appreciation of sepsis pathophysiology.

Authors:  J L Vincent
Journal:  Crit Care       Date:  2001       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.